NCT02436707 2026-04-20
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Active not recruiting
Canadian Cancer Trials Group
Mayo Clinic
SecuraBio
Hoffmann-La Roche
ADC Therapeutics S.A.